Merimepodib, an IMPDH inhibitor, suppresses replication of Zika virus and other emerging viral pathogens
- PMID: 29126899
- DOI: 10.1016/j.antiviral.2017.11.004
Merimepodib, an IMPDH inhibitor, suppresses replication of Zika virus and other emerging viral pathogens
Abstract
Zika virus (ZIKV), a member of the Flaviviridae family, has recently been linked to abnormal pregnancies, fetal death, microcephaly, and Guillain-Barré syndrome in humans. Merimepodib (MMPD, VX-497), a potent inhibitor of inosine-5'-monophosphate dehydrogenase (IMPDH), has shown antiviral activity against HCV and a variety of DNA and RNA viruses in vitro. In this report, we expand the antiviral spectrum of MMPD, and demonstrate that MMPD inhibits ZIKV RNA replication with an EC50 of 0.6 μM. Furthermore, MMPD reduces the virus production of ZIKV as well as several other important emerging viral pathogens such as Ebola, Lassa, Chikungunya, and Junin viruses. The inhibition can be reversed by addition of exogenous guanosine to culture media, consistent with the mechanism of action of MMPD as an IMPDH inhibitor. We also provide evidence that MMPD can be used in combination with other antivirals such as ribavirin and T-705 (favipiravir) to enhance suppression of virus production.
Keywords: Antiviral; Ebola; IMPDH; Merimepodib; VX-497; Zika.
Copyright © 2017 Elsevier B.V. All rights reserved.
Similar articles
-
Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon.Antimicrob Agents Chemother. 2000 Apr;44(4):859-66. doi: 10.1128/AAC.44.4.859-866.2000. Antimicrob Agents Chemother. 2000. PMID: 10722482 Free PMC article.
-
Identification of Inhibitors of ZIKV Replication.Viruses. 2020 Sep 18;12(9):1041. doi: 10.3390/v12091041. Viruses. 2020. PMID: 32961956 Free PMC article.
-
Evaluation of anti-Zika virus activities of broad-spectrum antivirals and NIH clinical collection compounds using a cell-based, high-throughput screen assay.Antiviral Res. 2017 Feb;138:47-56. doi: 10.1016/j.antiviral.2016.11.018. Epub 2016 Dec 3. Antiviral Res. 2017. PMID: 27919709
-
Autophagy in Zika Virus Infection: A Possible Therapeutic Target to Counteract Viral Replication.Int J Mol Sci. 2019 Feb 28;20(5):1048. doi: 10.3390/ijms20051048. Int J Mol Sci. 2019. PMID: 30823365 Free PMC article. Review.
-
Treating HCV with ribavirin analogues and ribavirin-like molecules.J Antimicrob Chemother. 2006 Jan;57(1):8-13. doi: 10.1093/jac/dki405. Epub 2005 Nov 17. J Antimicrob Chemother. 2006. PMID: 16293677 Review.
Cited by
-
Ribavirin for treating Lassa fever: A systematic review of pre-clinical studies and implications for human dosing.PLoS Negl Trop Dis. 2022 Mar 30;16(3):e0010289. doi: 10.1371/journal.pntd.0010289. eCollection 2022 Mar. PLoS Negl Trop Dis. 2022. PMID: 35353804 Free PMC article.
-
Scalable, compressed phenotypic screening using pooled perturbations.Nat Biotechnol. 2024 Oct 7. doi: 10.1038/s41587-024-02403-z. Online ahead of print. Nat Biotechnol. 2024. PMID: 39375446
-
Therapeutic strategies to target the Ebola virus life cycle.Nat Rev Microbiol. 2019 Oct;17(10):593-606. doi: 10.1038/s41579-019-0233-2. Epub 2019 Jul 24. Nat Rev Microbiol. 2019. PMID: 31341272 Review.
-
Drug repurposing approach to combating coronavirus: Potential drugs and drug targets.Med Res Rev. 2021 May;41(3):1375-1426. doi: 10.1002/med.21763. Epub 2020 Dec 5. Med Res Rev. 2021. PMID: 33277927 Free PMC article. Review.
-
Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors.Front Cell Infect Microbiol. 2019 Mar 26;9:67. doi: 10.3389/fcimb.2019.00067. eCollection 2019. Front Cell Infect Microbiol. 2019. PMID: 30972303 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical